Boundless Bio restructures pipeline, cuts workforce 33%, discontinues BBI-355 monotherapy

Boundless Bio, Inc.

Workforce reduction of ~1/3; expects $1.2M one-time costs, substantially completed in Q2 2025.
Discontinues current POTENTIATE trial arms for BBI-355 due to narrow therapeutic index and poor tolerability.
Plans to develop BBI-355/BBI-825 combination; initial clinical data expected within extended cash runway.
Selects BBI-940 as Kinesin program candidate; IND submission expected first half 2026.
Cash, equivalents & investments $138.3M as of March 31, 2025; operating runway extended into first half 2028.

item 2.05item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.